Pharming Group reports fourth quarter and full year 2023 financial results
The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
- The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
- Revenues increased to US$7.9 million in the fourth quarter of 2023, driven by the continued increase in patients on paid therapy, and revenues were US$18.2 million for 2023.
- Pharming made continued progress in the fourth quarter of 2023 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
- Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.